SAN DIEGO, Nov. 14, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that the company's late-breaking oral presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco November 13-17, 2015, was one of 16 selected as key abstracts (from among the 2,299 abstracts accepted for presentation at The Liver Meeting®) to be highlighted by Gyongy Szabo, M.D., Ph.D., in the AASLD President's press conference at 4:00 p.m. PST today. The late-breaking presentation (#LB6), entitled "Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with...
↧